# US 2022/0031810 A1 · Formulations of glucagon-like-peptide-2 (glp-2) analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031810 A1
- Document ID: US20220031810A1
- Status: Published application
- Kind: A1
- Application number: 17/279,691
- Filed: 2019-09-27
- Published: 2022-02-03
- Earliest claimed: 2018-09-28
- Assignees: Zealand Pharma A/S
- Applicants: Zealand Pharma A/S
- Inventors: Henrik Rajesh Kumar PARSHAD; Lise GIEHM; Claes MELANDER
- Web page: https://patentgrep.com/patent/US20220031810A1

## CPC

- A61K 38/26: Glucagons
- C07K 14/605: Glucagons
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Liquid formulations of GLP-2 analogues are described that make it possible to include a preservative while allowing the formulation to be stabilised for long term storage as liquids and/or as multi-dose liquid formulations. The development of these formulations is base on the finding that that reducing the pH of the formulation to below 7.0, e.g. to a pH between about pH 5.0 and about 6.8, was able to offset the effect that the addition of a preservative such as meta-cresol has on the physical stability of the formulation. Additionally, the addition of an excipient such as propylene glycol was shown to be able to offset the effect that the addition of a preservative, such as meta-cresol, has on the physical stability of the formulation. This opens up the possibility of being able to deliver the GLP-2 analogues as multi-dose formulations, for example allowing the use of the formulations in a drug delivery device.

## Claims

### Claim 1

A stable liquid pharmaceutical multi-dose formulation, the formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
R1-Z1-His-Gly-Glu-Gly-X5-Phe-Ser-Ser-Glu-Leu-X11-
Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-
Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Z2-R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;
X5 is Ser or Thr;
X11 is Ala or Ser;
R2 is NH2 or OH; and
Z1 and Z2 are independently absent or a peptide sequence of 1-6 amino acid units of Lys;
or a pharmaceutically acceptable salt or derivative thereof;
wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 1 mg/mL to about 30 mg/mL;
(b) meta-cresol or phenol as a preservative at a concentration of 1.0 to 5.0 mg/mL;
(c) a buffer selected from the group consisting of a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer, the buffer being present at a concentration of about 5 mM to about 50 mM;
(d) a non-ionic tonicity modifier selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose at a concentration of about 20 mM to about 360 mM;
(e) a pH of about 5.0 to about 6.8.

### Claim 2

A stable liquid pharmaceutical multi-dose formulation, the formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
R1-Z1-His-Gly-Glu-Gly-X5-Phe-Ser-Ser-Glu-Leu-X11-
Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-
Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Z2-R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl;
X5 is Ser or Thr;
X11 is Ala or Ser;
R2 is NH2 or OH; and
Z1 and Z2 are independently absent or a peptide sequence of 1-6 amino acid units of Lys;
or a pharmaceutically acceptable salt or derivative thereof;
wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 1 mg/mL to about 30 mg/mL;
(b) meta-cresol or phenol as a preservative at a concentration of 1.0 to 5.0 mg/mL;
(c) a buffer selected from the group consisting of a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer, the buffer being present at a concentration of about 5 mM to about 50 mM;
(d) a non-ionic tonicity modifier selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose at a concentration of about 20 mM to about 360 mM;
(e) a pH of about 5.5 to about 7.0; and
(f) propylene glycol at a concentration of 20 mM to 300 mM.

### Claim 3 (depends on 2)

The formulation of claim 2, wherein the formulation comprises propylene glycol at a concentration of 20 mM to 300 mM.

### Claim 4 (depends on 2, 3)

The formulation of claim 2 or claim 3, wherein the formulation comprises propylene glycol at a concentration of 50 mM to 200 mM.

### Claim 5 (depends on 1, 2, 3, 4)

The formulation according to any one of claims 1 to 4, wherein the formulation is an aqueous formulation.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The formulation according to any one of claims 1 to 5, wherein the formulation is stable for at least 18 months when stored at 2-8° C.

### Claim 7

The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is present in the formulation at a concentration of about 1 mg/mL to about 20 mg/mL.

### Claim 8

The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is present in the formulation at a concentration of about 2 mg/mL to about 15 mg/mL.

### Claim 9

The formulation according to any one of the preceding claims, wherein the formulation is a ready-to-use formulation.

### Claim 10

The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is present in the formulation at a concentration of about 2 mg/mL, 10 mg/mL or 20 mg/mL.

### Claim 11

The formulation according to any one of the preceding claims, wherein the histidine buffer is present in the formulation at a concentration of about 5 mM to about 25 mM.

### Claim 12 (depends on 11)

The formulation according to claim 11, wherein the histidine buffer is present in the formulation at a concentration of about 15 mM.

### Claim 13

The formulation according to any one of the preceding claims, wherein the mannitol is present in the formulation at a concentration of about 150 mM to about 250 mM.

### Claim 14 (depends on 13)

The formulation according to claim 13, wherein the mannitol is present in the formulation at a concentration of about 230 mM.

### Claim 15 (depends on 1)

The formulation according to claim 1, wherein the formulation has a pH of about 6.2 to about 6.8.

### Claim 16 (depends on 2)

The formulation according to claim 2, wherein the formulation has a pH of about 6.0 to about 7.0.

### Claim 17 (depends on 1)

The formulation according to claim 1, wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 2 mg/mL to about 20 mg/mL;
(b) meta-cresol as a preservative at a concentration of 1.0 to 5.0 mg/mL;
(c) a histidine buffer at a concentration of about 5 mM to about 50 mM;
(d) mannitol as a non-ionic tonicity modifier at a concentration of about 20 mM to about 360 mM; and
(e) a pH of about 6.0 to about 6.8.

### Claim 18 (depends on 1, 17)

The formulation according to claim 1 or claim 17, wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 1 mg/mL or about 10 mg/mL;
(b) a meta-cresol as a preservative at a concentration of 3.0 to 4.0 mg/mL;
(c) a histidine buffer at a concentration of about 10 mM to about 20 mM;
(d) mannitol as a non-ionic tonicity modifier at a concentration of about 200 mM to about 250 mM; and
(e) a pH of about 6.0 to about 6.8.

### Claim 19 (depends on 1, 17, 18)

The formulation according to any one of claim 1, 17 or 18, wherein the formulation consists of the GLP-2 analogue at a concentration of about 2 mg/mL or about 10 mg/mL; a meta-cresol as a preservative at a concentration of 3.0 to 4.0 mg/mL; a histidine buffer at a concentration of about 10 mM to about 20 mM; mannitol as a non-ionic tonicity modifier at a concentration of about 200 mM to about 250 mM; the formulation having a pH of about 6.0 to about 6.8.

### Claim 20 (depends on 2)

The formulation according to claim 2, wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 5 mg/mL to about 20 mg/mL;
(b) meta-cresol as a preservative at a concentration of 1.0 to 5.0 mg/mL;
(c) a histidine buffer at a concentration of about 5 mM to about 50 mM;
(d) mannitol as a non-ionic tonicity modifier at a concentration of about 20 mM to about 360 mM;
(e) a pH of about 5.0 to about 7.0; and
(f) propylene glycol at a concentration of 20 mM to 300 mM.

### Claim 21 (depends on 2, 20)

The formulation according to claim 2 or claim 20, wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 10 mg/mL;
(b) a meta-cresol as a preservative at a concentration of 3.0 to 4.0 mg/mL;
(c) a histidine buffer at a concentration of about 10 mM to about 20 mM;
(d) mannitol as a non-ionic tonicity modifier at a concentration of about 50 mM to about 230 mM; and
(e) a pH of about 5.0 to about 7.0; and
(f) propylene glycol at a concentration of 50 mM to 200 mM.

### Claim 22 (depends on 2, 20, 21)

The formulation according to any one of claim 2, 20 or 21, wherein the formulation consists of the GLP-2 analogue at a concentration of about 10 mg/mL; meta-cresol as a preservative at a concentration of 3.0 to 4.0 mg/mL; histidine buffer at a concentration of about 10 mM to about 20 mM; mannitol as a non-ionic tonicity modifier at a concentration of about 50 mM to about 230 mM; and propylene glycol at a concentration of 50 mM to 200 mM, the formulation having a pH of about 5.0 to about 7.0.

### Claim 23

The formulation according to any one of the preceding claims, wherein the histidine buffer is L-histidine.

### Claim 24

The formulation according to any one of the preceding claims, wherein the mannitol is D-mannitol.

### Claim 25

The formulation according to any one of the preceding claims, wherein the formulation is stable at 2-8° C. for at least 6 months, at least 12 months, at least 18 months or at least 24 months.

### Claim 26 (depends on 25)

The formulation according to claim 25, wherein the GLP-2 analogue in the formulation retains at least about 90% of its biological activity after 18 months of storage 2-8° C.

### Claim 27

The formulation according to any one of the preceding claims which is sterile.

### Claim 28

The formulation according to any one of the preceding claims, wherein the formulation is administration to a subject by injection.

### Claim 29 (depends on 28)

The formulation according to claim 28, wherein the injection is subcutaneous injection.

### Claim 30

The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is provided as an acetate salt.

### Claim 31

The formulation according to any one of the preceding claims, wherein the GLP-2 analogue is ZP1848 or ZP1848-acetate.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

An article of manufacture or a kit comprising a container holding the stable pharmaceutical formulation of any one of claims 1 to 31.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A delivery device containing a liquid formulation comprising a GLP-2 analogue of any one of claims 1 to 31.

### Claim 34 (depends on 33)

The delivery device of claim 33, wherein the delivery device is pre-filled syringe, an injector device, an injector pen, an adjustable dose auto-injector, a disposable auto-injector, a wearable injector, or an infusion pump.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A formulation of the glucagon-like peptide 2 (GLP-2) analogue of any one of claims 1 to 31 for use in therapy.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A formulation of the glucagon-like peptide 2 (GLP-2) analogue of any one of claims 1 to 31 for use in a method for the treatment and/or prevention of a stomach and/or bowel-related disorder in a human patient.

### Claim 37 (depends on 36)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in the method of treatment and/or prevention of claim 36, wherein the stomach and/or bowel-related disorder is ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue (for example arising from gluten induced enteropathy or celiac disease), tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), ulcerative colitis, small intestine damage or short bowel syndrome (SBS).

### Claim 38 (depends on 37)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in the method of treatment and/or prevention of claim 37, wherein the stomach and/or bowel-related disorder is short bowel syndrome.

### Claim 39 (depends on 36)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 36, wherein the stomach and/or bowel-related disorder is radiation enteritis, infectious or post-infectious enteritis, or small intestinal damage due to toxic or other chemotherapeutic agents.

### Claim 40 (depends on 39)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 39, wherein treatment with the GLP-2 analogue is combined with one or more anti-cancer therapies.

### Claim 41 (depends on 40)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 40, wherein treatment the anti-cancer therapy comprises administering one or more chemotherapeutic agent(s) to the patient or treating the patient with radiation therapy.

### Claim 42 (depends on 40, 41)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 40 or claim 41, wherein the formulation is used in the treatment and/or prevention of a side effect of chemotherapy or radiation treatment.

### Claim 43 (depends on 42)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to claim 42, wherein the side effect of chemotherapy is diarrhoea, abdominal cramping, vomiting or structural and functional damage of the intestinal epithelium resulting from chemotherapy treatment.

### Claim 44 (depends on 40, 41, 42, 43)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 40 to 43, wherein the human patient is a patient having SBS-intestinal failure.

### Claim 45 (depends on 40, 41, 42, 43, 44)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 40 to 44, wherein the human patient is a patient being on the border between being a patient having SBS-intestinal insufficiency and SBS-intestinal failure.

### Claim 46 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 35 to 45, wherein the method comprises administering the GLP-2 analogue to the patient once or twice daily.

### Claim 47 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The formulation of the glucagon-like peptide 2 (GLP-2) analogue for use in a method for the treatment according to any one of claims 29 to 45, wherein the method comprises administering the GLP-2 analogue to the patient once or twice weekly.

### Claim 48

Use of a formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
R1-Z1-His-Gly-Glu-Gly-X5-Phe-Ser-Ser-Glu-Leu-X11-
Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-
Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Z2-R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl
X5 is Ser or Thr
X11 is Ala or Ser
R2 is NH2 or OH;
Z1 and Z2 are independently absent or a peptide sequence of 1-6 amino acid units of Lys;
or a pharmaceutically acceptable salt or derivative thereof;
for providing an liquid pharmaceutical formulation which is stable for 18 months when stored at 2-8° C., wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 1 mg/mL to about 30 mg/mL;
(b) meta-cresol or phenol as a preservative at a concentration of 1.0 to 5.0 mg/mL;
(c) a buffer selected from the group consisting of a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer, the buffer being present at a concentration of about 5 mM to about 50 mM;
(d) a non-ionic tonicity modifier selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose at a concentration of about 20 mM to about 360 mM;
(e) a pH of about 5.0 to about 6.8.

### Claim 49

Use of a formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
R1-Z1-His-Gly-Glu-Gly-X5-Phe-Ser-Ser-Glu-Leu-X11-
Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-
Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Z2-R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl
X5 is Ser or Thr
X11 is Ala or Ser
R2 is NH2 or OH;
Z1 and Z2 are independently absent or a peptide sequence of 1-6 amino acid units of Lys;
or a pharmaceutically acceptable salt or derivative thereof;
for providing an liquid pharmaceutical formulation which is stable for 18 months when stored at 2-8° C., wherein the formulation comprises:
wherein the formulation comprises:
(a) the GLP-2 analogue at a concentration of about 1 mg/mL to about 30 mg/mL;
(b) meta-cresol or phenol as a preservative at a concentration of 1.0 to 5.0 mg/mL;
(c) a buffer selected from the group consisting of a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer, the buffer being present at a concentration of about 5 mM to about 50 mM;
(d) a non-ionic tonicity modifier selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose at a concentration of about 20 mM to about 360 mM;
(e) a pH of about 5.5 to about 7.0; and
(f) propylene glycol at a concentration of 20 mM to 300 mM.

### Claim 50

A process for producing a stable liquid pharmaceutical formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
R1-Z1-His-Gly-Glu-Gly-X5-Phe-Ser-Ser-Glu-Leu-X11-
Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-
Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Z2-R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl
X5 is Ser or Thr
X11 is Ala or Ser
R2 is NH2 or OH;
Z1 and Z2 are independently absent or a peptide sequence of 1-6 amino acid units of Lys;
or a pharmaceutically acceptable salt or derivative thereof;
wherein the process comprising formulating (a) the GLP-2 analogue at a concentration of about 1 mg/mL to about 30 mg/mL; (b) meta-cresol or phenol as a preservative at a concentration of 1.0 to 5.0 mg/mL; (c) a buffer selected from the group consisting of a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer, the buffer being present at a concentration of about 5 mM to about 50 mM; (d) a non-ionic tonicity modifier selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose at a concentration of about 20 mM to about 360 mM; at a pH of about 5.0 to about 6.8.

### Claim 51

A process for producing a stable liquid pharmaceutical formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, wherein the GLP-2 analogue is represented by the formula:
R1-Z1-His-Gly-Glu-Gly-X5-Phe-Ser-Ser-Glu-Leu-X11-
Thr-Ile-Leu-Asp-Ala-Leu-Ala-Ala-Arg-Asp-Phe-Ile-
Ala-Trp-Leu-Ile-Ala-Thr-Lys-Ile-Thr-Asp-Z2-R2
wherein:
R1 is hydrogen, C1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl
X5 is Ser or Thr
X11 is Ala or Ser
R2 is NH2 or OH;
Z1 and Z2 are independently absent or a peptide sequence of 1-6 amino acid units of Lys;
or a pharmaceutically acceptable salt or derivative thereof;
wherein the process comprising formulating (a) the GLP-2 analogue at a concentration of about 1 mg/mL to about 30 mg/mL; (b) meta-cresol or phenol as a preservative at a concentration of 1.0 to 5.0 mg/mL; (c) a buffer selected from the group consisting of a histidine buffer, mesylate buffer, acetate buffer, glycine buffer, lysine buffer, TRIS buffer, Bis-Tris buffer and MOPS buffer, the buffer being present at a concentration of about 5 mM to about 50 mM; (d) a non-ionic tonicity modifier selected from the group consisting of mannitol, sucrose, glycerol, sorbitol and trehalose at a concentration of about 20 mM to about 360 mM; (e) propylene glycol at a concentration of 20 mM to 300 mM; at a pH of about 5.5 to about 7.0.
